HIFU With Ablatherm(R) Now Available in Canada for Patients With Prostate Cancer
11 Abril 2005 - 9:29AM
PR Newswire (US)
HIFU With Ablatherm(R) Now Available in Canada for Patients With
Prostate Cancer LYON, France, April 11 /PRNewswire-FirstCall/ --
EDAP TMS S.A. (NASDAQ:EDAP) today announced its highly effective,
non-invasive treatment for prostate cancer is now available to
North American patients through a clinical installation in Toronto,
Canada. Prostate cancer is the leading cancer among North American
men and is second only to lung cancer as the cause of
cancer-related deaths in North American males. It is estimated that
approximately 250,000 new cases of prostate cancer are diagnosed in
North America each year. EDAP TMS and Maple Leaf HIFU Company have
entered into an exclusive sales agreement allowing Maple Leaf to
market the Ablatherm(R) in Canada and develop access to
Ablatherm(R)-HIFU technology throughout the Canadian territory. The
Ablatherm(R)-HIFU prostate cancer treatment is now being offered at
the Don Mills Surgical Unit in Toronto. The Don Mills Surgical Unit
is a private surgical facility that is licensed by the Province of
Ontario and under the direction of Dr. William Orovan, a board
certified urologist and chair of the Department of Surgery,
McMaster University. Additionally, Dr. Orovan is the former
president of the Ontario Medical Association. Ablatherm(R)-HIFU is
an effective treatment for patients with localized prostate cancer
whose disease is confined to the prostate gland itself, referred to
as clinical stage T1 or T2. Ablatherm(R)-HIFU can also be performed
on patients who have undergone radiation treatment in the past and
experienced recurrent cancer. The HIFU procedure provides these
patients with a treatment option when few others remain.
Ablatherm(R)-HIFU is approved for use in Canada and throughout
Europe where it has more than 8 years of patient follow-up data.
While the technology does not currently have United States FDA
approval, clinical trials are expected to begin soon.
Ablatherm(R)-HIFU is a proven technology developed and perfected in
Europe with clinical experience now exceeding 7,000 treatments.
This procedure offers a safe and effective alternative to more
radical treatments such as surgery or radiation, currently the
primary treatment methods. European studies have shown that as a
curative option Ablatherm(R)-HIFU has had success rates up to 93%,
with five years of follow- up. Ablatherm(R)-HIFU can be repeated
and does not exclude patients from undergoing other treatment
options if their cancer is found to be more aggressive or
recurring. "This clinically proven treatment is a revolutionary
advance in the ongoing fight against Prostate Cancer," said Dr.
John Warner, a Memorial Sloan-Kettering trained uro-oncologist
practicing in Vancouver, Canada. "We are excited to finally bring
the Ablatherm(R)-HIFU treatment to North America so many more can
discover its benefits." Ablatherm(R)-HIFU is a non-invasive,
precise, and targeted procedure that delivers a beam of high
intensity focused ultrasound to the prostate. Under spinal
anesthesia, the Ablatherm(R)-HIFU probe is placed into the rectum
through which the focused ultrasound waves are directed into the
cancerous prostate tissue without damage to the intervening tissue.
This causes a rapid rise in temperature inside the prostate cells
to 85 degrees Celsius, destroying the cancerous cells. The
procedure is completed in 2 to 3 hours without blood loss or
exposure to radiation. "We are pleased and excited to bring this
technology to Canada after so many years of success in Europe,"
said Hugues de Bantel, Chief Executive Officer of EDAP TMS.
"Ablatherm(R)-HIFU is a proven alternative to existing treatments
for prostate cancer with a low occurrence of side effects, thus
preserving patients quality of life. We believe Canada represents a
significant and important opportunity to bring this treatment
technology and its benefits to men suffering from prostate cancer
in North America." David Lowy, President of Maple Leaf HIFU
Company, added, "We are proud to be the first to bring this
innovative technique, proven in Europe for years, to North American
patients suffering from prostate cancer. We anticipate that many
patients will choose to be treated in Toronto with
Ablatherm(R)-HIFU and avoid surgery or radiotherapy. Patients and
physicians can visit http://www.hifu.ca/ for further information."
About EDAP TMS S.A. EDAP TMS S.A. develops and markets
Ablatherm(R), the most advanced and clinically proven choice for
High Intensity Focused Ultrasound (HIFU) treatment of localized
prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side
effects. The company is also developing this technology for the
treatment of certain other types of tumors. EDAP TMS S.A. also
produces and commercializes medical equipment for treatment of
urinary tract stones using Extra-corporeal Shockwave Lithotripsy
(ESWL). For more information on the Company, contact the Investor
Relations Dept. by phone at +33 4 78 26 40 46, or see the Company's
Web site at: http://www.edap-tms.com/ . About Maple Leaf HIFU Co.
Maple Leaf HIFU Co. is a privately held Canadian medical services
company offering treatments using Ablatherm(R)-High Intensity
Focused Ultrasound treatments for localized prostate cancer.
Further information can be found at http://www.hifu.ca/ . This
press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described
in the Company's filings with the Securities and Exchange
Commission. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe
Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor
Relations Matt Kreps - Geralyn DeBusk 972 458 8000 DATASOURCE: EDAP
TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine
Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or
Geralyn DeBusk , both of Halliburton Investor Relations,
+1-972-458-8000, for EDAP TMS S.A. Web site:
http://www.edap-tms.com/ http://www.hifu.ca/
Copyright
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024